ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

BGNE BeiGene Ltd

162.48
0.23 (0.14%)
07 5월(5) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
BeiGene Ltd BGNE 나스닥 주식예탁증서 (DR)
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
0.23 0.14% 162.48 09:00:00
개장가 저가 고가 종가 전일 종가
164.51 161.945 165.00 162.48 162.25
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
26/04/202423:34BWBeiGene Demonstrates Global Progress in 2023 Responsible..
25/04/202420:11BWGlobaler Onkologie-Innovator BeiGene präsentiert auf der..
25/04/202420:10BWBeiGene, innovateur mondial en oncologie, présente de..
25/04/202405:01BWGlobal Oncology Innovator BeiGene Highlights New Data across..
24/04/202408:31BWBeiGene erhält von der EU-Kommission die Zulassung für..
23/04/202419:00BWBeiGene Receives European Commission Approval for..
17/03/202400:18BWBeiGene、化学療法後の進行性または転移性食道扁平上皮癌の治療のためのTEVIMBRA®のFDA承認取得
16/03/202406:13BW百濟神州喜獲FDA批准,TEVIMBRA®將用於晚期或轉移性食管鱗狀細胞癌在化療後的治療
16/03/202405:02BWBeiGene reçoit l'approbation de la FDA pour TEVIMBRA® dans..
15/03/202415:06BWBeiGene erhält FDA-Zulassung für TEVIMBRA ® zur Behandlung..
15/03/202405:28BWBeiGene Receives FDA Approval for TEVIMBRA® for the..
14/03/202423:23BWマックス財団、ベイジーン、ベイジーン財団の協力により、低・中所得国の慢性リンパ性白血病患者にBRUKINSA®を初回投与
14/03/202418:31BWThe Max Foundation、BeiGene和BeiGene..
14/03/202404:01BWErste Dosen von BRUKINSA ® für Patienten mit chronischer..
13/03/202421:00BWFirst Doses of BRUKINSA® provided to Patients with Chronic..
08/03/202407:19BWBeiGene Announces FDA Accelerated Approval of BRUKINSA for..
06/03/202420:00BWBeiGene to Present Clinical and Preclinical Data from Broad..
01/03/202401:17BWベイジーン、2023年第4・四半期および通期決算と事業に関する最新情報を発表
01/03/202400:00BWBeiGene Announces New Efficacy Analysis Comparing BRUKINSA®..
29/02/202409:56BWBeiGene publie ses résultats financiers du quatrième..
29/02/202403:13BWBeiGene meldet Finanzergebnisse für das vierte Quartal und..
28/02/202422:05BWBeiGene to Present at Upcoming Investor Conferences
28/02/202421:43BWベイジーン、非小細胞肺がん治療薬チスレリズマブに対してCHMPから肯定的意見を受領
28/02/202420:48BWBeiGene公布2023年第四季及全年財務業績和最新業務情況
27/02/202421:24BW百濟神州(BeiGene)獲得 CHMP 對替雷利珠單抗(Tislelizumab)治療非小細胞肺癌的積極意見
27/02/202421:22BWBeiGene erhält positives CHMP-Gutachten für Tislelizumab zur..
27/02/202420:00BWBeiGene’s Biologics License Application for TEVIMBRA®..
26/02/202420:02EDGAR2Form 8-K - Current report
26/02/202420:00BWBeiGene Reports Fourth Quarter and Full Year 2023 Financial..
26/02/202419:00BWBeiGene Receives Positive CHMP Opinion for Tislelizumab as..
07/02/202420:47PRNCASanté Canada approuve BRUKINSA® (zanubrutinib) dans le..
31/01/202420:47PRNCAAdults living with chronic lymphocytic leukemia (CLL) in..
25/01/202404:03BWベイジーン、取締役会に経験豊富なライフサイエンス界のエグゼクティブ、オリビエ・ブランディクールを迎える
24/01/202402:04BWBeiGene accueille au sein de son conseil d'administration,..
24/01/202401:55BWBeiGene heißt den erfahrenen Life Sciences Manager Olivier..
23/01/202420:03EDGAR2Form 8-K - Current report
23/01/202420:00BWBeiGene Welcomes Experienced Life Sciences Executive Olivier..
22/12/202320:00BWFDA Approves Label Update for BRUKINSA® (zanubrutinib) in..
21/12/202320:01BWBeiGene to Present at the 42nd Annual J.P. Morgan Healthcare..
30/11/202306:01BWBeiGene to Host ASH Investor Meeting in Person and via..
28/11/202320:00BWBeiGene to Present New Data Highlighting Hematology..
21/11/202320:00BWBeiGene and Ensem Therapeutics Announce Partnership to..
17/11/202320:00BWBeiGene Receives European Commission Approval for BRUKINSA®..
10/11/202306:08EDGAR2Form 8-K - Current report
10/11/202306:01BWBeiGene Continues Global Growth with Third Quarter 2023..
08/11/202320:00BWBeiGene to Present at the Jefferies London Healthcare..
21/10/202305:04EDGAR2Form 8-K - Current report
20/10/202319:00BWBRUKINSA® Receives Positive Recommendation from NICE in U.K...
18/10/202305:01BWBeiGene Announces the Phase 3 RATIONALE 315 Trial Met..
16/10/202319:00BWBeiGene Presentations at ESMO 2023 Demonstrate Robust..

최근 히스토리

Delayed Upgrade Clock